Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Countagen logo — Accelerating Genome Engineering

Countagen

Accelerating Genome Engineering

Founded 2020 Sweden Sweden 11 employees Series Unknown Total: $11.50M Biotechnology

General Information

Company Name Countagen
Founded Year 2020
Location Sweden Sweden +1
Employees 11
Industries Biotechnology
Funding Stage Series Unknown
Social

Get notified when Countagen moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Countagen

Countagen is an innovative biotechnology startup based in Sweden, founded in 2020. The company offers cutting-edge gene editing analysis tools, with their flagship product, GeneAbacus, catering to academia, biotech, and pharma sectors utilizing genome editing/CRISPR. Countagen's proprietary technology, with the recent kr11.50M Venture Round investment from Almi Invest on 27 June 2022, enables precise and rapid quantification of gene edits. Countagen's commitment to collaborative innovation and integrity ensures that their solutions pioneer excellence in gene editing analysis. The company's mission to accelerate access to the transformative power of gene editing through fast and precise quantification technology establishes it as a noteworthy player in the biotechnology industry. With their reagent kit condensing the turnaround time of pool analysis and clone selection to a single day, while ensuring high accuracy with standard lab equipment, Countagen's dedication to driving advancements in gene editing analysis positions them as an entity to watch in the biotech startup landscape.

Taxonomy: gene editing, quantification technology, biotech, pharmaceuticals, genome editing, CRISPR, reagent kit, research acceleration, innovation, integrity, precision technology, academic research, biotechnology tools

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round •••••• 1
Investor
27 Jun 2022

Countagen Alternatives & Competitors

Countagen vs
Virostem Biotechnology
Virostem Biotechnology Turkey

Gene Editing Technologies and Applications

2 employees
Biotechnology, Life Sciences
Countagen vs
EdiGene Inc.
EdiGene Inc. China

Edit the Code of Life, Creating Transformative Solutions for Serious Diseases.

Series B
46 employees
Biotechnology, Health Care
Countagen vs
Spotlight Therapeutics
Spotlight Therapeutics United States

Biotechnology company that develops biologics targeted to specific cell populations in gene editing

Series B
22 employees
Biotechnology, Health Care

FAQ About Countagen

Accelerating Genome Engineering
Countagen was founded in 2020.
Countagen is headquartered in Sweden.
Countagen operates in the following industries: Biotechnology.
Countagen has approximately 11 employees.
Countagen has completed 1 funding round, raising a total of $11.50M. The latest funding stage is Series Unknown.
Top alternatives and competitors to Countagen include Virostem Biotechnology, EdiGene Inc., Spotlight Therapeutics, Recombinetics, Precision BioSciences, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Countagen and Virostem Biotechnology are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Countagen and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy